Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 129-133, 2013.
Article
in English
| WPRIM
| ID: wpr-149906
ABSTRACT
The presence of epidermal growth factor receptor (EGFR) mutation is a prognostic and predictive marker for EGFR-tyrosine kinase inhibitor (TKI) therapy. However, inevitably, relapse occurs due to the development of acquired resistance, such as T790M mutation. We report a case of repeated responses to EGFR-TKIs in a never-smoked woman with adenocarcinoma. After six cycles of gemcitabine and cisplatin, the patient was treated by gefitinib for 4 months until progression. Following the six cycles of third-line pemetrexed, gefitinib retreatment was initiated and continued with a partial response for 6 months. After progression, she was recruited for an irreversible EGFR inhibitor trial, and the time to progression was 11 months. Although EGFR direct sequencing on the initial diagnostic specimen revealed a wild-type, we performed a rebiopsy from the progressed subcarinal node at the end of the trial. The result of peptide nucleic acid clamping showed L858R/L861Q.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phosphotransferases
/
Quinazolines
/
Recurrence
/
Adenocarcinoma
/
Cisplatin
/
Constriction
/
Retreatment
/
Deoxycytidine
/
Epidermal Growth Factor
/
ErbB Receptors
Type of study:
Prognostic study
Limits:
Female
/
Humans
Language:
English
Journal:
Tuberculosis and Respiratory Diseases
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS